<\/p>\n
Lefuheal<\/strong> is an oral tablet from Healing Pharma containing leflunomide 10 mg and 20 mg<\/strong> — an oral conventional synthetic DMARD<\/strong> (disease-modifying antirheumatic drug) that inhibits dihydroorotate dehydrogenase, blocking de-novo pyrimidine synthesis in activated lymphocytes. Used primarily for moderate-to-severe rheumatoid arthritis<\/strong> \u03ba\u03b1\u03b9 active psoriatic arthritis<\/strong>, usually after methotrexate has failed or as a methotrexate alternative. Standard adult dose: 20 mg \u03bc\u03b9\u03b1 \u03c6\u03bf\u03c1\u03ac \u03c4\u03b7\u03bd \u03b7\u03bc\u03ad\u03c1\u03b1<\/strong> (10 mg once daily if intolerance); some prescribers use a 100 mg\/day × 3-day loading dose, but this raises early hepatotoxicity and diarrhoea rates and is increasingly skipped in routine practice. Onset is slow — 4–6 weeks for early benefit, 12–24 weeks for full effect.<\/strong> The drug's active metabolite (teriflunomide) has an exceptionally long half-life (~14 days from a single dose, much longer with steady-state enterohepatic recirculation) — a feature that makes it convenient (once-daily dosing, missed dose forgiveness) but also means cholestyramine washout is mandatory<\/strong> for pregnancy planning, severe adverse reaction, or rapid switch to another therapy. Pregnancy Category X<\/strong> — both female AND male patients on leflunomide must use effective contraception. Hepatotoxicity is the major safety concern<\/strong>; monthly LFT\/CBC\/BP for 6 months then quarterly.<\/p>\n<\/div>\n <\/p>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n Lefuheal is an oral tablet manufactured by Healing Pharma containing leflunomide<\/strong> — a conventional synthetic disease-modifying antirheumatic drug (DMARD). Leflunomide itself is a pro-drug that is rapidly converted in the gut and liver to its active metabolite teriflunomide<\/strong> (also marketed as a separate drug for multiple sclerosis under the brand name Aubagio).<\/p>\n Lefuheal is Healing Pharma's branded generic leflunomide — available at both 10 mg and 20 mg strengths to support flexible dose titration. The 20 mg tablet is the standard maintenance dose; the 10 mg tablet is used for dose reduction in patients with intolerance (particularly diarrhoea, hair thinning, or mild ALT rise) and for elderly or low-body-weight patients. Leflunomide has been in routine rheumatology practice since the late 1990s; it is one of the few oral DMARDs with proven equivalent efficacy to methotrexate in rheumatoid arthritis. It is used either alongside methotrexate in resistant disease, or as the principal DMARD when methotrexate is not tolerated.<\/p>\n The active metabolite teriflunomide selectively inhibits dihydroorotate dehydrogenase (DHODH)<\/strong>, a mitochondrial enzyme central to de-novo pyrimidine synthesis<\/strong>. Activated, rapidly-dividing lymphocytes depend almost entirely on this de-novo pathway for the nucleotides they need to proliferate; resting and slowly-dividing cells can bypass DHODH using the salvage pathway.<\/p>\n The result is a selective brake on activated T-cell and B-cell proliferation:<\/p>\n Pharmacokinetic features that matter clinically:<\/strong><\/p>\n Lefuheal is \u03b4\u03b5\u03bd<\/strong> appropriate for: ankylosing spondylitis (no axial benefit), mild rheumatoid arthritis (sulfasalazine or hydroxychloroquine first), short-term symptom relief (the drug takes weeks to work), or patients who cannot commit to monthly blood tests for at least 6 months.<\/p>\n Lefuheal is supplied at 10 mg and 20 mg<\/strong>. Standard adult dosing is straightforward but requires careful upfront planning around contraception and baseline monitoring.<\/p>\n The active metabolite teriflunomide undergoes enterohepatic recirculation<\/strong>: it is excreted in bile, reabsorbed in the gut, and returned to the bloodstream. This is why teriflunomide stays measurable in plasma for many months after stopping leflunomide, and why a special washout is needed when rapid elimination is required.<\/p>\n \u03a7\u03bf\u03bb\u03b7\u03c3\u03c4\u03c5\u03c1\u03b1\u03bc\u03af\u03bd\u03b7<\/strong> (an oral bile-acid sequestrant) binds teriflunomide in the gut, breaking the enterohepatic loop and dramatically accelerating elimination.<\/p>\n Standard washout protocol:<\/strong><\/p>\n When to use the washout protocol:<\/strong><\/p>\n Without the washout, teriflunomide can persist in plasma for up to 2 years.<\/p>\n Leflunomide is generally tolerated similarly to methotrexate — about 1 in 5 patients stop the drug within the first year because of side effects.<\/p>\n Common (> 10%):<\/strong><\/p>\n Uncommon to rare but serious:<\/strong><\/p>\n Pregnancy and fertility:<\/strong><\/p>\n\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
What Is Lefuheal?<\/h2>\n
How Does Lefuheal Work?<\/h2>\n
\n
\n
\u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n
\n
Lefuheal Dosage and How to Take<\/h2>\n
Dosing options<\/h3>\n
\n\n
\n \nApproach<\/th>\n \u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/th>\n Trade-off<\/th>\n<\/tr>\n<\/thead>\n \n Loading dose (traditional)<\/strong><\/td>\n 100 mg once daily for 3 days, then 20 mg once daily<\/td>\n Faster steady-state by ~2 weeks but higher rates of early diarrhoea, hepatotoxicity, and discontinuation<\/td>\n<\/tr>\n \n No-loading (preferred in modern practice)<\/strong><\/td>\n 10–20 mg once daily from day one<\/td>\n Slower to steady-state; better tolerated; lower discontinuation. Steady-state reached at 8–12 weeks.<\/td>\n<\/tr>\n \n Reduced dose for tolerability<\/strong><\/td>\n 10 mg once daily ongoing<\/td>\n Useful when 20 mg\/day causes intolerable diarrhoea; some loss of efficacy<\/td>\n<\/tr>\n \n Combination with methotrexate<\/strong><\/td>\n 10–20 mg leflunomide + standard methotrexate<\/td>\n Higher efficacy but additive hepatotoxicity and infection risk; closer monitoring required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n How to Take Lefuheal Properly<\/h3>\n
\n
Cholestyramine Washout — Why and When<\/h2>\n
\n
\n
Side Effects of Lefuheal<\/h2>\n
\n
\n
\n
\u03a0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03ac\u03be\u03b5\u03b9\u03c2<\/h2>\n
\n
Contraindications — Who Should NOT Take Lefuheal<\/h2>\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n